Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis.
Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M. Roessler M, et al. Mol Cell Proteomics. 2006 Nov;5(11):2092-101. doi: 10.1074/mcp.M600118-MCP200. Epub 2006 Aug 6. Mol Cell Proteomics. 2006. PMID: 16893879 Free article.
A list of all identified proteins and validation of five exemplarily selected proteins, elevated in CRC was reported previously (Roessler, M., Rollinger, W., Palme, S., Hagmann, M. L., Berndt, P., Engel, A. M., Schneidinger, B., Pfeffer, M., And …
A list of all identified proteins and validation of five exemplarily selected proteins, elevated in CRC was reported previously (Roessler …
Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker.
Thierolf M, Hagmann ML, Pfeffer M, Berntenis N, Wild N, Roeßler M, Palme S, Karl J, Bodenmüller H, Rüschoff J, Rossol S, Rohr G, Rösch W, Friess H, Eickhoff A, Jauch KW, Langen H, Zolg W, Tacke M. Thierolf M, et al. Among authors: roessler m. Proteomics Clin Appl. 2008 Jan;2(1):11-22. doi: 10.1002/prca.200780046. Epub 2007 Dec 11. Proteomics Clin Appl. 2008. PMID: 21136775 No abstract available.
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, Schellens JH. Meulendijks D, et al. Among authors: roessler m. Clin Cancer Res. 2016 Feb 15;22(4):858-67. doi: 10.1158/1078-0432.CCR-15-1506. Epub 2015 Oct 7. Clin Cancer Res. 2016. PMID: 26446946 Clinical Trial.
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, Schellens JH, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD. Lassen UN, et al. Among authors: roessler m. Clin Cancer Res. 2015 Jan 15;21(2):258-66. doi: 10.1158/1078-0432.CCR-14-1334. Epub 2014 Nov 11. Clin Cancer Res. 2015. PMID: 25388164 Clinical Trial.
Chloride dependence of growth in bacteria.
Roessler M, Sewald X, Müller V. Roessler M, et al. FEMS Microbiol Lett. 2003 Aug 8;225(1):161-5. doi: 10.1016/S0378-1097(03)00509-3. FEMS Microbiol Lett. 2003. PMID: 12900036
189 results